CTKB has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CTKB has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Cytek Biosciences's enterprise value is $568.2 Mil. Cytek Biosciences's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $193.0 Mil. Therefore, Cytek Biosciences's EV-to-Revenue for today is 2.94.
The historical rank and industry rank for Cytek Biosciences's EV-to-Revenue or its related term are showing as below:
During the past 5 years, the highest EV-to-Revenue of Cytek Biosciences was 29.87. The lowest was 1.73. And the median was 7.58.
The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.
EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.
As of today (2024-05-05), Cytek Biosciences's stock price is $6.22. Cytek Biosciences's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $1.43. Therefore, Cytek Biosciences's PS Ratio for today is 4.36.
The historical data trend for Cytek Biosciences's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cytek Biosciences Annual Data | |||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||
EV-to-Revenue | - | - | 14.21 | 6.46 | 4.89 |
Cytek Biosciences Quarterly Data | |||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
EV-to-Revenue | Get a 7-Day Free Trial | 6.46 | 5.81 | 5.02 | 2.60 | 4.89 |
For the Medical Devices subindustry, Cytek Biosciences's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Cytek Biosciences's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Cytek Biosciences's EV-to-Revenue falls into.
EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.
Cytek Biosciences's EV-to-Revenue for today is calculated as:
EV-to-Revenue | = | Enterprise Value (Today) | / | Revenue (TTM) |
= | 568.190 | / | 193.014 | |
= | 2.94 |
Cytek Biosciences's current Enterprise Value is $568.2 Mil.
Cytek Biosciences's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $193.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cytek Biosciences (NAS:CTKB) EV-to-Revenue Explanation
The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.
Cytek Biosciences's PS Ratiofor today is calculated as:
PS Ratio | = | Share Price (Today) | / | Revenue per Share (TTM) |
= | 6.22 | / | 1.428 | |
= | 4.36 |
Cytek Biosciences's share price for today is $6.22.
Cytek Biosciences's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.43.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Cytek Biosciences's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Patrick Jeanmonod | officer: Chief Financial Officer | C/O CYTEK BIOSCIENCES, INC., 46107 LANDING PARKWAY, FREMONT CA 94538 |
Ming Yan | director, officer: Chief Technology Officer | C/O CYTEK BIOSCIENCES, INC., 46107 LANDING PARKWAY, FREMONT CA 94538 |
Wenbin Jiang | director, officer: President and CEO | C/O CYTEK BIOSCIENCES, INC., 46107 LANDING PARKWAY, FREMONT CA 94538 |
Philippe Busque | officer: SVP, Global Sales and Services | 47215 LAKEVIEW BOULEVARD, FREMONT CA 94538 |
Jack Ball | director | C/O CYTEK BIOSCIENCES, INC., 46107 LANDING PARKWAY, FREMONT CA 94538 |
Paul Christopher Williams | officer: Chief Operating Officer | C/O CYTEK BIOSCIENCES, INC., 47215 LAKEVIEW BOULEVARD, FREMONT CA 94538 |
Don M Hardison | director | |
Deborah J Neff | director | C/O CYTEK BIOSCIENCES, INC., 47215 LAKEVIEW BLVD., FREMONT CA 94538 |
Jonathan Todd Garland | officer: Chief Commercial Officer | C/O CYTEK BIOSCIENCES, INC., 47215 LAKEVIEW BOULEVARD, FREMONT CA 94538 |
Ra Capital Healthcare Fund Lp | director | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
Vera Imper | director | C/O CYTEK BIOSCIENCES, INC., 47215 LAKEVIEW BOULEVARD, FREMONT CA 94538 |
Theresa Cameron | director | C/O THERAPEUTICS ACQUISITION CORP., 200 BERKELEY STREET. 18TH F L, BOSTON MA 02116 |
Feng Deng | director | SUITE 1701, 17/F HUTCHISON HOUSE, 10 HARCOURT ROAD, CENTRAL, HONG KONG K3 00000 |
Ra Capital Nexus Fund Ii, L.p. | director | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
Rajeev M. Shah | director | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
From GuruFocus
By Stock market mentor Stock market mentor • 02-07-2023
By GuruFocus Research • 09-21-2023
By Marketwired • 09-27-2023
By Marketwired • 07-20-2023
By Stock market mentor Stock market mentor • 02-07-2023
By sperokesalga sperokesalga • 05-19-2023
By Marketwired • 09-14-2023
By Marketwired • 08-08-2023
By sperokesalga sperokesalga • 05-31-2023
By GuruFocus Research • 10-12-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.